SENZAGEN AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.32 SEK | +1.97% |
|
-1.89% | +28.02% |
| May. 15 | SenzaGen AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 25 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
Presentation Operator MessageOperator (Operator)Welcome to the SenzaGen AB Audiocast for Telec...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.
Calendar
2024-08-14
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +28.02% | 20.66M | |
| -31.90% | 9.59B | |
| -6.25% | 3.21B | |
| +25.95% | 2.92B | |
| -13.96% | 2.15B | |
| -16.83% | 1.79B | |
| +72.82% | 1.47B | |
| +29.17% | 770M | |
| -2.62% | 761M | |
| -26.33% | 548M |
- Stock Market
- Equities
- SENZA Stock
- News SenzaGen AB
- Transcript : SenzaGen AB, H1 2021 Earnings Call, Aug 19, 2021
